Survival outcome of patients with screening versus symptomatically detected colorectal cancers
Survival outcome of patients with screening versus symptomatically detected colorectal cancers
复制标题
DOI：
10.1111/j.1463-1318.2012.03120.x
复制
发表时间：
2013-01-01
影响因子：
3.4
通讯作者：
Harmston, C.
中科院分区：
文献类型：
--
作者：
Pande, R.;Froggatt, P.;Harmston, C.
目标 在英国两个卫生当局进行试点筛查后，国家肠癌筛查计划已在全国范围内推广。本研究的目的是确定筛查检测到的癌症的总体 5 年生存率，并比较筛查患者与有症状患者在 10 年内的总体生存结果。 方法 对试点筛查计划（2000-2008 年）期间在筛查年龄（50-69 岁）患者中接受单一信托治疗的所有结直肠癌患者进行分析。患者被定义为筛查检测到或症状检测到的患者。疾病病理学和复发数据来自医院的计算机化结果报告系统，死亡率与西米德兰兹癌症情报网络的数据进行交叉匹配。 结果 研究期间总共确定了 633 名年龄在 50-69 岁之间的患者； 155 名患者的筛查发现了癌症，478 名患者没有发现癌症。对生存结果完成的对数秩检验表明，有症状组的生存率明显较差。如果仅考虑以治疗为目的的患者，这种差异仍然存在。 结论 在所有组中，筛查人群的生存结果明显优于有症状的人群，在以治疗为目的的治疗中也是如此。与阶段相比，筛查检测到的癌症有更好的生存趋势。
Aim The national Bowel Cancer Screening Programme has been rolled out nationwide following pilot screening in two health authorities in the UK. The aim of this study was to define overall 5-year survival of screen detected cancers and to compare the overall survival outcome of screened vs symptomatic patients over a 10-year period.Method All patients with colorectal cancer treated at one trust in patients of screening age (50-69 years) during the pilot screening programme (2000-2008) were analysed. Patients were defined as screen detected or symptomatically detected. Disease pathology and recurrence data were obtained from the hospital's computerized results reporting system and mortality was cross-matched with data from the West Midlands Cancer Intelligence Network.Results In all, 633 patients aged 50-69 were identified in the study period; 155 patients had a screen detected cancer and 478 did not. A log-rank test completed on survival outcomes indicated that survival was significantly worse in the symptomatic group. This difference persisted if only patients treated with curative intent were considered.Conclusion Survival outcome was significantly better in the screened vs the symptomatic population in all groups and also in those treated for curative intent. There was a trend towards better survival for screen detected cancer when compared stage for stage.